ATE448306T1 - Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung - Google Patents
Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellungInfo
- Publication number
- ATE448306T1 ATE448306T1 AT01966492T AT01966492T ATE448306T1 AT E448306 T1 ATE448306 T1 AT E448306T1 AT 01966492 T AT01966492 T AT 01966492T AT 01966492 T AT01966492 T AT 01966492T AT E448306 T1 ATE448306 T1 AT E448306T1
- Authority
- AT
- Austria
- Prior art keywords
- conformation
- protein
- production
- desired conformation
- stabilized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22970000P | 2000-09-01 | 2000-09-01 | |
PCT/US2001/027227 WO2002018583A2 (en) | 2000-09-01 | 2001-08-31 | Modified polypeptides stabilized in a desired conformation and methods for producing same |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE448306T1 true ATE448306T1 (de) | 2009-11-15 |
Family
ID=22862353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01966492T ATE448306T1 (de) | 2000-09-01 | 2001-08-31 | Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung |
Country Status (8)
Country | Link |
---|---|
US (6) | US7160541B2 (de) |
EP (1) | EP1315812B1 (de) |
JP (1) | JP5113314B2 (de) |
AT (1) | ATE448306T1 (de) |
AU (1) | AU2001287000A1 (de) |
CA (1) | CA2417432C (de) |
DE (1) | DE60140457D1 (de) |
WO (1) | WO2002018583A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2554965C (en) * | 2004-02-19 | 2015-08-11 | The Cbr Institute For Biomedical Research, Inc. | Antibodies specific for activated conformation of lfa-1 |
US7240492B2 (en) * | 2004-07-22 | 2007-07-10 | Sprint Communications Company L.P. | Fuel system used for cooling purposes |
US7081687B2 (en) * | 2004-07-22 | 2006-07-25 | Sprint Communications Company L.P. | Power system for a telecommunications facility |
ATE555202T1 (de) | 2004-08-16 | 2012-05-15 | Immune Disease Inst Inc | Verfahren zur lieferung von rna-interferenz und verwendungen damit |
US20070018182A1 (en) * | 2005-07-20 | 2007-01-25 | Goldeneye, Inc. | Light emitting diodes with improved light extraction and reflectivity |
US20090291048A1 (en) * | 2005-10-25 | 2009-11-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Leukocyte-binding polypeptides and uses thereof |
US8021668B2 (en) * | 2005-12-12 | 2011-09-20 | Immune Disease Institute, Inc. | Integrin alpha L I domain mutants with increased binding affinity |
WO2007127272A2 (en) * | 2006-04-24 | 2007-11-08 | The Cbr Institute For Biomedical Research | Method of producing immunoliposomes and compositions thereof |
EP2018436A2 (de) * | 2006-04-25 | 2009-01-28 | Immune Disease Institute Inc. | Gezielte abgabe an leukozyten mit nicht-proteinträgern |
AU2007256780B2 (en) | 2006-06-02 | 2013-08-29 | President And Fellows Of Harvard College | Protein surface remodeling |
CN101490548A (zh) * | 2006-06-02 | 2009-07-22 | 哈佛大学校长及研究员协会 | 蛋白质表面重建 |
US20120328628A1 (en) * | 2006-07-07 | 2012-12-27 | The Regents Of The University Of California | Antibodies to conformationally trapped proteins |
AU2009243187C1 (en) * | 2008-04-28 | 2015-12-24 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
US8877893B2 (en) * | 2008-12-29 | 2014-11-04 | Children's Medical Center Corporation | Stabilized low affinity conformation of integrins for drug discovery |
JP2012525146A (ja) | 2009-04-28 | 2012-10-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 細胞透過のための過剰に荷電されたタンパク質 |
PL3326645T3 (pl) * | 2010-10-25 | 2020-09-21 | Biogen Ma Inc. | Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM |
US20120258041A1 (en) * | 2011-04-07 | 2012-10-11 | Basi Guriqbal S | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition |
WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
CA2880117C (en) | 2012-07-27 | 2021-04-06 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
US9880179B2 (en) * | 2013-02-05 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Method for selecting agents that bind to transmembrane receptors in a conformationally selective manner |
WO2020205827A1 (en) * | 2019-04-01 | 2020-10-08 | Rush University Medical Center | Reagents and assays using modified integrin domains |
US11100297B2 (en) * | 2019-04-15 | 2021-08-24 | International Business Machines Corporation | Provision of natural language response to business process query |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
WO1988006592A1 (en) * | 1987-02-26 | 1988-09-07 | Dana-Farber Cancer Institute, Inc. | Cloning of lfa-1 |
US5512660A (en) * | 1987-05-04 | 1996-04-30 | Dana Farber Cancer Institute, Inc. | Purified ICAM-2 and fragment thereof |
US5831036A (en) * | 1987-05-04 | 1998-11-03 | Dana Farber Cancer Institute | Soluble fragments of human intercellular adhesion molecule-1 |
US5489533A (en) * | 1987-05-04 | 1996-02-06 | Dana Farber Cancer Institute | Isolated nucleic acid molecules encoding ICAM-2 |
US5565550A (en) * | 1987-05-04 | 1996-10-15 | Dana Farber Cancer Institute | Antibodies to ICAM-2, and fragments thereof |
US5284931A (en) * | 1987-05-04 | 1994-02-08 | Dana Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5395929A (en) * | 1987-12-15 | 1995-03-07 | Dana Farber Cancer Institute | Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor |
EP0364690A3 (de) * | 1988-08-23 | 1990-07-18 | Dana Farber Cancer Institute | Alpha-Subeinheit des Mac-1-Leukocyt-Adhäsions-Rezeptors |
DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US6511664B1 (en) * | 1989-03-09 | 2003-01-28 | Dana Farber Cancer Institute | Intercellular adhesion molecule—2 and its binding ligands |
US6797270B1 (en) * | 1989-03-16 | 2004-09-28 | Center For Blood Research, Inc. | Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy |
US6777191B1 (en) * | 1989-03-16 | 2004-08-17 | Center For Blood Research, Inc. | Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in diagnosis of viral infection |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
DE69033493D1 (de) | 1989-07-25 | 2004-08-12 | Cell Genesys Inc | Homologe rekombination für universelle donorzellen und chimerische säugetierzellen |
NZ236792A (en) | 1990-01-19 | 1993-05-26 | Merck & Co Inc | Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5393788A (en) | 1990-07-10 | 1995-02-28 | Smithkline Beecham Corporation | Phenylalkyl oxamides |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5288854A (en) * | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
EP0575485A1 (de) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Verfahren zur entwicklung bindender miniproteine |
US5460945A (en) * | 1991-05-30 | 1995-10-24 | Center For Blood Research, Inc. | Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response |
US5891841A (en) * | 1991-06-11 | 1999-04-06 | The Center For Blood Research, Inc. | Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof |
AU675916B2 (en) * | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
WO1993023526A1 (en) * | 1992-05-21 | 1993-11-25 | Center For Blood Research, Inc. | A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON |
ES2112431T3 (es) | 1992-08-21 | 1998-04-01 | Genentech Inc | Procedimiento para el tratamiento de un trastorno mediado por lfa-1. |
US5877295A (en) * | 1992-09-30 | 1999-03-02 | The Center For Blood Research | Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen |
US5514555A (en) * | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
US5470953A (en) * | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
GB2298520B (en) * | 1995-03-03 | 1999-09-08 | Hong Chen Fu In | Heat sink device for integrated circuit |
US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) * | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5747035A (en) * | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US6121022A (en) * | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5888765A (en) | 1995-06-23 | 1999-03-30 | President And Fellows Of Harvard College | Endothelial-cell specific promoter |
US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
US5914112A (en) * | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
US5843712A (en) * | 1996-06-06 | 1998-12-01 | The Trustees Of Columbia University In The City Of New York | Sindbis virus expression system for recombinant antibody production |
WO1998023761A1 (en) * | 1996-11-27 | 1998-06-04 | Genentech, Inc. | HUMANIZED ANTI-CD11a ANTIBODIES |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
JP2001510483A (ja) * | 1997-06-13 | 2001-07-31 | ジェネンテク,インコーポレイテッド | タンパク質の回収 |
US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
US6582698B1 (en) * | 1999-03-19 | 2003-06-24 | Genentech, Inc. | Treatment method |
SG83788A1 (en) | 1999-04-13 | 2001-10-16 | Mitsui Chemicals Inc | Method for preparing polymer |
ATE403437T1 (de) * | 1999-12-14 | 2008-08-15 | Genentech Inc | Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis |
JP3933847B2 (ja) | 2000-06-19 | 2007-06-20 | ユニ・チャーム株式会社 | 吸収性物品 |
AU2001282880A1 (en) * | 2000-07-07 | 2002-01-21 | California Institute Of Technology | Proteins with integrin-like activity |
-
2001
- 2001-08-31 US US09/945,265 patent/US7160541B2/en not_active Expired - Lifetime
- 2001-08-31 EP EP01966492A patent/EP1315812B1/de not_active Expired - Lifetime
- 2001-08-31 AU AU2001287000A patent/AU2001287000A1/en not_active Abandoned
- 2001-08-31 CA CA2417432A patent/CA2417432C/en not_active Expired - Fee Related
- 2001-08-31 WO PCT/US2001/027227 patent/WO2002018583A2/en active Application Filing
- 2001-08-31 AT AT01966492T patent/ATE448306T1/de not_active IP Right Cessation
- 2001-08-31 DE DE60140457T patent/DE60140457D1/de not_active Expired - Lifetime
- 2001-08-31 JP JP2002522490A patent/JP5113314B2/ja not_active Expired - Lifetime
-
2005
- 2005-03-15 US US11/080,043 patent/US7674604B2/en not_active Expired - Fee Related
- 2005-03-15 US US11/080,026 patent/US7241869B2/en not_active Expired - Fee Related
-
2009
- 2009-11-20 US US12/592,275 patent/US7879577B2/en not_active Expired - Fee Related
-
2010
- 2010-12-10 US US12/964,813 patent/US7968284B2/en not_active Expired - Fee Related
-
2011
- 2011-06-22 US US13/165,873 patent/US8241627B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2417432A1 (en) | 2002-03-07 |
US20110111528A1 (en) | 2011-05-12 |
WO2002018583A2 (en) | 2002-03-07 |
JP5113314B2 (ja) | 2013-01-09 |
DE60140457D1 (de) | 2009-12-24 |
US20050260192A1 (en) | 2005-11-24 |
AU2001287000A1 (en) | 2002-03-13 |
US20020123614A1 (en) | 2002-09-05 |
EP1315812A2 (de) | 2003-06-04 |
WO2002018583A9 (en) | 2003-10-30 |
EP1315812B1 (de) | 2009-11-11 |
US8241627B2 (en) | 2012-08-14 |
US7241869B2 (en) | 2007-07-10 |
US20050182244A1 (en) | 2005-08-18 |
US20110305691A1 (en) | 2011-12-15 |
US7160541B2 (en) | 2007-01-09 |
US20100113742A1 (en) | 2010-05-06 |
JP2004527217A (ja) | 2004-09-09 |
WO2002018583A3 (en) | 2003-01-30 |
US7968284B2 (en) | 2011-06-28 |
US7879577B2 (en) | 2011-02-01 |
CA2417432C (en) | 2010-11-02 |
US7674604B2 (en) | 2010-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE448306T1 (de) | Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung | |
BRPI0516011A (pt) | moléculas fc modificadas | |
ECSP055849A (es) | Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico | |
BRPI0412007A (pt) | mutagênese look-through | |
CY1108691T1 (el) | Πολυπεπτιδια | |
ATE361364T1 (de) | Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen | |
NO20025354L (no) | Pattedyr-reseptorproteiner; beslektede reagenser og fremgangsmåter | |
ATE480562T1 (de) | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese | |
DE69412614D1 (de) | Recombinante disulfid-stabilisierte polypeptide mit bindung spezifität | |
ES2187954T3 (es) | Anticuerpos anti-integrina avb3 antagonistas. | |
DE59309458D1 (de) | Synthetische Peptide, Antikörper dagegen und ihre Verwendung | |
ATE148168T1 (de) | Monoklonale antikörper | |
DE69942668D1 (de) | Humanisierter monoklonaler antikörper gegen von-willebrand faktor | |
DE60129239D1 (de) | Kit und verfahren zur bestimmung von protein esm-1 | |
DE60034117D1 (de) | Verfahren zur herstelllung von gonadotropin-zusammensetzungen | |
ATE234918T1 (de) | Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen | |
ATE407208T1 (de) | Hemopoietin-rezeptor | |
Rentier et al. | The 3‐nitro‐2‐pyridinesulfenyl group: synthesis and applications to peptide chemistry | |
ATE433463T1 (de) | Monospezifische antikörper gegen fibrinogen und fibrinopeptide b | |
ATE331732T1 (de) | Schaumproteine, monoklonale antikörper dagegen, und deren verwendungen | |
KR900012626A (ko) | 하이브리드 단백질, 이의 생산방법 및 이를 함유하는 약제학적 조성물 | |
Harmand | Molecular interface characterization in human bone matrix: I. Biochemical and IR spectroscopic studies | |
Lugovskoy et al. | Functional role of Bβ‐chain N‐terminal fragment in the fibrin polymerization process | |
ATE428721T1 (de) | Verfahren zur herstellung von wachstumshormon und antagonisten davon mit geringeren konzentrationen an isoformen verunreinigungen davon | |
Feng et al. | Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |